Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1

Charles Lawrence Loprinzi, Rui Qin, Ernie P. Baclueva, Kathleen A. Flynn, Kendrith M. Rowland, David L. Graham, Nancy K. Erwin, Shaker R. Dakhil, Donald J. Jurgens, Kelli N. Burger

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Purpose: Hot flashes are a common problem for which effective and safe treatments are needed. The current trial was conducted on the basis of preliminary promising data that pregabalin decreased hot flashes. Patients and Methods: A double-blind, placebo-controlled, randomized trial design was used to compare pregabalin at target doses of 75 mg twice daily and 150 mg twice daily with a placebo. Hot flash frequencies and scores (frequency times mean severity) were recorded daily during a baseline week and for six treatment weeks. The primary end point for this study was the change-from-baseline hot flash score during treatment week 6 between the 150 mg twice daily target pregabalin treatment and placebo. Nonparametric Wilcoxon rank sum tests, two-sample t tests, and χ2 tests were used to compare the primary and secondary hot flash efficacy end points between pregabalin treatments and placebo. Results: Hot flash score changes available for 163 patients during the sixth treatment week compared with a baseline week decreased by 50%, 65%, and 71% in the placebo, and target 75 mg twice daily and 150 mg twice daily pregabalin arms, respectively (P = .009 and P = .007, comparing respective pregabalin arms to the placebo arm). While some toxicities were significantly more common in the pregabalin arms, being more evident with the higher dose, pregabalin was generally well tolerated by most patients. Conclusion: Pregabalin decreases hot flashes and is reasonably well tolerated. A target dose of 75 mg twice daily is recommended. Its effects appear to be roughly comparable to what has been reported with gabapentin and with some newer antidepressants.

Original languageEnglish (US)
Pages (from-to)641-647
Number of pages7
JournalJournal of Clinical Oncology
Volume28
Issue number4
DOIs
StatePublished - Feb 1 2010

Fingerprint

Hot Flashes
Placebos
Nonparametric Statistics
Therapeutics
Pregabalin
Double-Blind Method
Antidepressive Agents
Randomized Controlled Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. / Loprinzi, Charles Lawrence; Qin, Rui; Baclueva, Ernie P.; Flynn, Kathleen A.; Rowland, Kendrith M.; Graham, David L.; Erwin, Nancy K.; Dakhil, Shaker R.; Jurgens, Donald J.; Burger, Kelli N.

In: Journal of Clinical Oncology, Vol. 28, No. 4, 01.02.2010, p. 641-647.

Research output: Contribution to journalArticle

Loprinzi, CL, Qin, R, Baclueva, EP, Flynn, KA, Rowland, KM, Graham, DL, Erwin, NK, Dakhil, SR, Jurgens, DJ & Burger, KN 2010, 'Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1', Journal of Clinical Oncology, vol. 28, no. 4, pp. 641-647. https://doi.org/10.1200/JCO.2009.24.5647
Loprinzi, Charles Lawrence ; Qin, Rui ; Baclueva, Ernie P. ; Flynn, Kathleen A. ; Rowland, Kendrith M. ; Graham, David L. ; Erwin, Nancy K. ; Dakhil, Shaker R. ; Jurgens, Donald J. ; Burger, Kelli N. / Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 4. pp. 641-647.
@article{99d15c09549d4c68bd79908b858ffaf0,
title = "Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1",
abstract = "Purpose: Hot flashes are a common problem for which effective and safe treatments are needed. The current trial was conducted on the basis of preliminary promising data that pregabalin decreased hot flashes. Patients and Methods: A double-blind, placebo-controlled, randomized trial design was used to compare pregabalin at target doses of 75 mg twice daily and 150 mg twice daily with a placebo. Hot flash frequencies and scores (frequency times mean severity) were recorded daily during a baseline week and for six treatment weeks. The primary end point for this study was the change-from-baseline hot flash score during treatment week 6 between the 150 mg twice daily target pregabalin treatment and placebo. Nonparametric Wilcoxon rank sum tests, two-sample t tests, and χ2 tests were used to compare the primary and secondary hot flash efficacy end points between pregabalin treatments and placebo. Results: Hot flash score changes available for 163 patients during the sixth treatment week compared with a baseline week decreased by 50{\%}, 65{\%}, and 71{\%} in the placebo, and target 75 mg twice daily and 150 mg twice daily pregabalin arms, respectively (P = .009 and P = .007, comparing respective pregabalin arms to the placebo arm). While some toxicities were significantly more common in the pregabalin arms, being more evident with the higher dose, pregabalin was generally well tolerated by most patients. Conclusion: Pregabalin decreases hot flashes and is reasonably well tolerated. A target dose of 75 mg twice daily is recommended. Its effects appear to be roughly comparable to what has been reported with gabapentin and with some newer antidepressants.",
author = "Loprinzi, {Charles Lawrence} and Rui Qin and Baclueva, {Ernie P.} and Flynn, {Kathleen A.} and Rowland, {Kendrith M.} and Graham, {David L.} and Erwin, {Nancy K.} and Dakhil, {Shaker R.} and Jurgens, {Donald J.} and Burger, {Kelli N.}",
year = "2010",
month = "2",
day = "1",
doi = "10.1200/JCO.2009.24.5647",
language = "English (US)",
volume = "28",
pages = "641--647",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1

AU - Loprinzi, Charles Lawrence

AU - Qin, Rui

AU - Baclueva, Ernie P.

AU - Flynn, Kathleen A.

AU - Rowland, Kendrith M.

AU - Graham, David L.

AU - Erwin, Nancy K.

AU - Dakhil, Shaker R.

AU - Jurgens, Donald J.

AU - Burger, Kelli N.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Purpose: Hot flashes are a common problem for which effective and safe treatments are needed. The current trial was conducted on the basis of preliminary promising data that pregabalin decreased hot flashes. Patients and Methods: A double-blind, placebo-controlled, randomized trial design was used to compare pregabalin at target doses of 75 mg twice daily and 150 mg twice daily with a placebo. Hot flash frequencies and scores (frequency times mean severity) were recorded daily during a baseline week and for six treatment weeks. The primary end point for this study was the change-from-baseline hot flash score during treatment week 6 between the 150 mg twice daily target pregabalin treatment and placebo. Nonparametric Wilcoxon rank sum tests, two-sample t tests, and χ2 tests were used to compare the primary and secondary hot flash efficacy end points between pregabalin treatments and placebo. Results: Hot flash score changes available for 163 patients during the sixth treatment week compared with a baseline week decreased by 50%, 65%, and 71% in the placebo, and target 75 mg twice daily and 150 mg twice daily pregabalin arms, respectively (P = .009 and P = .007, comparing respective pregabalin arms to the placebo arm). While some toxicities were significantly more common in the pregabalin arms, being more evident with the higher dose, pregabalin was generally well tolerated by most patients. Conclusion: Pregabalin decreases hot flashes and is reasonably well tolerated. A target dose of 75 mg twice daily is recommended. Its effects appear to be roughly comparable to what has been reported with gabapentin and with some newer antidepressants.

AB - Purpose: Hot flashes are a common problem for which effective and safe treatments are needed. The current trial was conducted on the basis of preliminary promising data that pregabalin decreased hot flashes. Patients and Methods: A double-blind, placebo-controlled, randomized trial design was used to compare pregabalin at target doses of 75 mg twice daily and 150 mg twice daily with a placebo. Hot flash frequencies and scores (frequency times mean severity) were recorded daily during a baseline week and for six treatment weeks. The primary end point for this study was the change-from-baseline hot flash score during treatment week 6 between the 150 mg twice daily target pregabalin treatment and placebo. Nonparametric Wilcoxon rank sum tests, two-sample t tests, and χ2 tests were used to compare the primary and secondary hot flash efficacy end points between pregabalin treatments and placebo. Results: Hot flash score changes available for 163 patients during the sixth treatment week compared with a baseline week decreased by 50%, 65%, and 71% in the placebo, and target 75 mg twice daily and 150 mg twice daily pregabalin arms, respectively (P = .009 and P = .007, comparing respective pregabalin arms to the placebo arm). While some toxicities were significantly more common in the pregabalin arms, being more evident with the higher dose, pregabalin was generally well tolerated by most patients. Conclusion: Pregabalin decreases hot flashes and is reasonably well tolerated. A target dose of 75 mg twice daily is recommended. Its effects appear to be roughly comparable to what has been reported with gabapentin and with some newer antidepressants.

UR - http://www.scopus.com/inward/record.url?scp=77449122836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449122836&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.24.5647

DO - 10.1200/JCO.2009.24.5647

M3 - Article

VL - 28

SP - 641

EP - 647

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -